RTP Mobile Logo
Investigator Perspectives on the Prevalence and Clinical Implications of Inaccurate or Misclassified Lymphoma Diagnoses in Community Oncology Practice (Video Program)
Released February 2018

Featuring interviews with Drs Mitchell R Smith, Fernando Cabanillas and Randy David Gascoyne on potential strategies to improve diagnostic accuracy in the field of lymphoma and chronic lymphocytic leukemia. (Video Program)

CE Disclosures and Faculty Information

    This activity is intended for medical oncologists, hematologists, hematology-oncology fellows and other healthcare providers involved in the treatment of hematologic cancers.

    The misclassification of lymphoma is a common clinical reality that can impede effective therapeutic decision-making and compromise outcomes for patients. A number of factors can lead to misdiagnosis in these cases. However, many may be mitigated through multidisciplinary collaboration and awareness. To this end, this CME activity encourages exchange between medical oncologists and hematopathologists, reviews available information and helps better define strategies to improve diagnostic accuracy.


    • Recognize common practical impediments (eg, inadequate sample size) to the accurate diagnostic assessment of lymphoid tissue, and use this information to improve internal and external processes and procedures.
    • Empower oncologists to more actively assess pathologic reporting to identify factors that could lead to misinterpretation.
    • Promote interdisciplinary collaboration between oncologists and pathologists to improve the accuracy of lymphoma subclassification.
    • Highlight the importance of immunohistochemistry (IHC) for lymphoma classification, and alert oncologists to the challenges associated with its interpretation.
    • Appreciate the specific IHC markers that should be included in a standard lymphoma panel, and discern how the selection and use of these markers differ in lymphoma subclassification.
    • Increase awareness of the incidence and relevance of CD30 overexpression in patients with T-cell lymphoma, Hodgkin lymphoma and diffuse large B-cell lymphoma, and develop strategies to appropriately determine CD30 positivity.
    • Formulate an evidence-based approach to biomarker analysis (cytogenetics, mutation status, et cetera) for patients with newly diagnosed and relapsed/refractory chronic lymphocytic leukemia, and appreciate the therapeutic implications of relevant findings.

    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    CME credit is no longer available for this issue

    CME credit is no longer available for this issue

    This CME activity consists of a video component.
    CME credit is no longer available for this issue

    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:

    Mitchell R Smith, MD, PhD
    Professor of Medicine
    Associate Center Director for Clinical Investigations
    Division of Hematology and Oncology
    George Washington Cancer Center
    Washington, DC

    Advisory Committee: Genentech BioOncology, Seattle Genetics; Contracted Research: Celgene Corporation, Takeda Oncology; Educational Presentation: AstraZeneca Pharmaceuticals LP.

    Fernando Cabanillas, MD
    Clinical Professor of Medicine
    The University of Texas MD Anderson Cancer Center
    Houston, Texas
    Medical Director
    Auxilio Mutuo Cancer Center
    San Juan, Puerto Rico

    Advisory Committee: Lilly, Merck, Pfizer Inc; Consulting Agreement: Bristol-Myers Squibb Company; Contracted Research: Abbott Laboratories, Celgene Corporation.

    Randy David Gascoyne, MD
    Hematopathologist, Clinical Professor of Pathology
    University of British Columbia
    Research Director, Centre for Lymphoid Cancer
    Department Head, Lymphoid Cancer Research
    British Columbia Cancer Agency
    Medical Director, Provincial Lymphoma Pathology Program
    Distinguished Scientist
    British Columbia Cancer Research Centre
    Vancouver, British Columbia, Canada

    No relevant conflicts of interest to disclose.

    EDITOR — Dr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma, Adaptive Biotechnologies, Agendia Inc, Agios Pharmaceuticals Inc, Amgen Inc, Ariad Pharmaceuticals Inc, Array BioPharma Inc, Astellas Pharma Global Development Inc, AstraZeneca Pharmaceuticals LP, Baxalta Inc, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Pharma Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, CTI BioPharma Corp, Dendreon Pharmaceuticals Inc, Eisai Inc, Exelixis Inc, Foundation Medicine, Genentech BioOncology, Genomic Health Inc, Gilead Sciences Inc, Halozyme Inc, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Kite Pharma Inc, Lexicon Pharmaceuticals Inc, Lilly, Medivation Inc, a Pfizer Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, NanoString Technologies, Natera Inc, Novartis, Novocure, Onyx Pharmaceuticals, an Amgen subsidiary, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seattle Genetics, Sigma-Tau Pharmaceuticals Inc, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro Inc, Teva Oncology and Tokai Pharmaceuticals Inc.

    RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no relevant conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This activity is supported by educational grants from AbbVie Inc and Seattle Genetics.

    Hardware/Software Requirements:
    A high-speed Internet connection
    A monitor set to 1280 x 1024 pixels or more
    Internet Explorer 11 or later, Firefox 56 or later, Chrome 61 or later, Safari 11 or later, Opera 48 or later
    Adobe Flash Player 27 plug-in or later
    Adobe Acrobat Reader
    (Optional) Sound card and speakers for audio

    Last review date: February 2018
    Expiration date: February 2019

Acknowledge and close

Watch videos
(WIFI is recommended for best performance):

Interview with Mitchell R Smith, MD, PhD

Interview with Fernando Cabanillas, MD

Interview with Randy David Gascoyne, MD

Select Publications